Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • S110: A NOVEL AND SUCCESSFUL C...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES

S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES

Bibliographic Details
Main Authors: J. Yang, J. Li, X. Zhang, L. Qiu, P. Lu
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000843336.97011.4c
  • Holdings
  • Description
  • Similar Items
  • Staff View
Description
ISSN:2572-9241

Similar Items

  • Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
    by: Yinqiang Zhang, et al.
    Published: (2023-04-01)
  • Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
    by: Elad Jacoby
    Published: (2019-06-01)
  • Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
    by: Hujun Li, et al.
    Published: (2022-10-01)
  • P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
    by: Y. Zhang, et al.
    Published: (2022-06-01)
  • Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
    by: Shuyi Ding, et al.
    Published: (2023-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs